🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
7.35
+0.01 (0.14%)
At close: Nov 19, 2026, 4:00 PM EST
7.41
+0.06 (0.82%)
After-hours: Nov 19, 2026, 7:56 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Ziftomenib reached 150 new patient starts last quarter, up ~30% QoQ, with combinations used in half of patients. Frontline trial data are expected to begin in 2028, while funding supports ziftomenib and darlifarnib development.

Moderator

All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, Senior Analyst, [inaudible] Biotech in the U.S. It is my pleasure to have the fireside chat with Kura Oncology. We have Chief Commercial Officer, Brian Powl, and then we have Chief Financial Officer, Jennifer Fulk, and then we also have Chief Medical Officer, Mollie Leoni . Welcome. Awesome. Maybe Brian, I will start with you because you have a commercial product, and then they are launching pretty well for the ziftomenib. So, I think the launch trajectory looks pretty good as a second to the market. What have been the key driver for this market-leading menin inhibitor launch, and then how you think about the sustainability and then maintain this leadership position?

Brian Powl
Chief Commercial Officer, Kura Oncology

Absolutely. Thanks, Roger, and thanks for having us host this fireside for us. Yeah, I would say that our commercial presence so far has really out-executed what we even expected. Coming in second to market, we knew that we would have to basically grow our patient starts, and we achieved our actually majority share of new patient starts in the second quarter of launch, in the second quarter of the year, and we maintained that this year.

What we have seen is a lot of success from our commercial team in terms of executing. First off, we had a very rapid uptake from our payer support. So, we have over nearly 100% of our accounts, patients' lives are covered. But we also had a rapid adoption in the academic accounts that you would expect to see treat the relapsed/refractory NPM1 mutant population. So, we have seen a lot of continued growth.

This last quarter, we had growth in both our new patient starts, so we are now at 150 new patient starts, which is about 30% growth quarter-on-quarter. We also had an increase in our total prescriptions of 60% quarter-on-quarter, which is showing that we are getting deeper penetration and patients are staying on drug longer. So, we are very pleased with where it starts. We anticipate that we expect to see further growth over the course of the next several quarters, where we will be able to penetrate and see more patients treated with a menin inhibitor and continue to treat with and build our leadership position that we have started so far this year.

Moderator

Got it. And then how should we think about the duration of treatment? I know it is still early days, right? But you have some early adopters, and then when they see the patient, and then understanding this is a relapsed/refractory setting, typically patient not going to respond too well, unfortunately. But how do you think the ziftomenib is changing the disease course, maybe can allow them to respond a bit longer?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, absolutely. Yeah, so, as we've guided before, the relapsed/refractory market we see for the NPM1 population is essentially the TAM of about $350 million-$400 million a year. That's assuming that you'll have NPM1 mutated patients, which is about 30% of the market, able to be treated for about six months of treatment. So, that study showed between five to six months of treatment for patients. I outline that market scope because it really essentially has several options. Patients can either get treated by a single agent menin inhibitor in the relapse, third, fourth line, or even in the second line setting. But there are other options like VenAza for patients who haven't seen venetoclax or for patients who may be co-mutated with FLT3.

30% of patients with AML have FLT3 mutation, and about half of those also have an NPM1 co-mutation. So, we see the duration right now so far has been with those first patients that come on, it takes time for us to really see how duration may pull out. Our expectation is that as patients are treated potentially in combination, which is not part of our label, but it's been something that physicians are using spontaneously to use KOMZIFTI in combination, would allow for treatment earlier in their disease, which could potentially lead to longer durations as well.

Moderator

Got it. Speaking of the combination, I think Kura has been always say your combinability is the one in the future for ziftomenib. Is that true in the real world? Do you see more combination for ziftomenib versus other menin inhibitor? And then if so, do you see that, as you mentioned, the duration of treatment and duration of response is much longer for the patient?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah. I think that part of the reason why we were confident in our leadership position moving into the relapsed/refractory AML space is because we believe KOMZIFTI has the right balance between four key areas. It's the efficacy, it's the safety and tolerability that's favorable. We have the combinability and the compatibility with other agents, like concomitant agents, like azoles and others without dose modification, and also the simplicity of a once-daily dosing. And those four features have really been pulled together from physicians and read back to us from physicians, that we see that the combinability is such an important aspect of treatment. And we anticipate that with data that we've been generating over the last several years, that we'll be able to show that we'll be able to treat or help physicians make the decisions to treat how they want to treat AML.

One of the things we've heard since we launched KOMZIFTI is that the data, efficacy data, safety data as a monotherapy is impressive to physicians, but their goal is to optimize the outcomes for patients and use these agents in combination. We think that the opportunity for combination, in the last quarter, in fact, we actually had 50% of our patients were now being used in combination. The good majority of those are actually in combination with venetoclax/azacitidine. The others are actually had some patients treated with FLT3 inhibitors as well in those co-mutated population. We published data from our KOMET-007 study looking at ziftomenib plus VenAza in the relapsed/refractory setting earlier this year in Blood, that physicians, I think, are seeing and using that information to help them to support their treatment decisions.

We will be presenting additional data that Mollie can talk about in combination with FLT3 inhibitors coming forward at ASH as well.

Moderator

Yeah. We'll talk about the ASH in one moment. Okay, just on that point, do you think the combinability and then the half of the patient, more than half of patient on combo, that's one of the key driver you can get to the leadership position for menin inhibitor so quickly, even as the second-

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, I do think that's a factor, and I think that physicians see the ability to be able to combine as a benefit that they'd like to put for their AML patients as early as in their treatment course as possible. I think a second-line patient who's on a treatment may have a better outcome than someone who's in third or fourth line, who've seen multiple lines of therapy. So we do think that the combination approach is, and the desire to combine and the ability to combine so well is one of the differentiating features that allow KOMZIFTI to potentially have that leadership position as we go forward.

Moderator

Got it. Okay, great. Let's talk about ASH, Mollie. Kura is going to have a lot of updates there, and then many of them are incremental, but FLT3 combination, that is the first time we see that. We already saw the abstract, but that is also very major updates you will have, which other menin inhibitor did not have it. Maybe just to give you a minute, what would be the key focus for ASH for Kura this year, and then we can talk about the competitor as well.

Mollie Leoni
Chief Medical Officer, Kura Oncology

Yeah. For us, the key purpose of ASH is to expand both the breadth of who we can treat and with what we can treat. As we are referring to, there is going to be several presentations. One of them is going to be actually expanding beyond NPM1 mutants and KMT2A rearranged patients into other subtypes that are actually menin dependent, and that is very important. We have always said that we think we can treat 50% of AML, and now we are showing you those data. The other very important piece, besides updating you on our frontline VenAza data with longer follow-up to show you that all of the assumptions we made in designing our pivotal frontline trial are actually very much holding true, and so that we have a lot of confidence in the trial as we designed it, is really this FLT3 data.

FLT3 is important because it is half of your NPM1 mutants. While there are other menin inhibitors out there on the market treating NPM1, they cannot treat the FLT3 mutants simultaneously with another targeted agent. We think that this is something very important. So we have designed two different trials to look at FLT3. One is in the relapsed/refractory setting with gilteritinib, and that trial has shown a very good combinability, which competitors have not been able to do. It shows a very good response rate. It shows ability to get patients to their transplants. Really, to me, what it shows is do not sequence these drugs, use them in combination. I think that is what physicians have been waiting to understand, is that a possibility?

Because why wait for someone to fail a therapy if you can make them have a better response for a longer period of time by combining? That is what I would look for with our relapsed/refractory gilteritinib data. Then we will be presenting our quad data with quizartinib, zifto, plus 7+3 . That is obviously in the frontline. It is hard to do better than 100% CRC rate, so it looks fantastic. The safety, again, very tolerable. This is one of those stories that will be exciting to share with you over time, because it really will be, hopefully, a very long story with a very long duration of response, with a very long overall survival. Those are the pieces that we will start fleshing out over time. But that is really how we are both getting more patients and getting more combinations in our data at ASH.

Moderator

Thank you, Mollie. I think those are two, actually, the two data sets are very critical. Though, as we discussed earlier, in the commercial setting, you start to see a lot of the combination use. Is that true? Right now, the combination mostly is still the VenAza combination because that's in the second line. All the other 7+3 and then VenAza quad is in the first line. So with this FLT3, will you start to see more FLT3 in the R/R setting, and then the overall combination usage will even grow beyond 50%, or are they switching? Because right now, maybe they are FLT3, but they are using VenAza because you don't have data to support, because I believe you have the VenAza in R/R setting already.

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah. I would say that I think a lot of our physicians have told us that they'd like to just see some data to better characterize and understand how they could use KOMZIFTI in combination. We've already seen some of the patients that are getting combination right now in the relapsed refractory setting. It's not all VenAza, it's a lot of VenAza, but there are some FLT3 with gilteritinib.

Moderator

Yeah.

Brian Powl
Chief Commercial Officer, Kura Oncology

We anticipate that as we present the data and we show how we can characterize it, physicians have told us they want data, number of patients to be confident to be able to use that, may help to drive that. So it's not obviously part of our promotional efforts, but that's where physicians, I think, want to go, and I think that's what's so valuable about the data that we're presenting.

Moderator

Got it. Okay. On the first line, you already reported multiple times at the different conference for the past couple years for the first line data. Understanding first line, it'll be harder bar to use, spontaneous or off-label use. Do you think at what point before you read out the pivotal first-line data, then the physician will feel comfortable to use, even try in the first line. I don't know if they already tried, but just how likely and when they will be able to do that?

Mollie Leoni
Chief Medical Officer, Kura Oncology

Well, I want all the patients to come into my trial because I really would like to finish my trial. But the ones that can't, we've already heard anecdotal evidence that there's some reason that they're not eligible or they can't make the site or something, that there will be some use in the frontline setting. But right now, I think that really is a studies place, a trials place to establish the drugs. What will take to establish them more use? Honestly, I think it'll be as these spaces in these trials fill and the desire to continue treating with this combination remains, you'll start to see more and more, and that'll bleed up until we get the approval in the frontline.

Moderator

Yeah. That's fair. Okay. On the competitive side, I think when we see the abstract and a lot of the stock reaction and pretty volatile, I don't know if that's the key driver, but at least J&J reported pretty impressive relapsed refractory data for their menin inhibitor, and then also another company, Sumitomo also reporting some interesting data. I talked with some physician, yeah, they also feel that data is pretty good. So, from your perspective, your commercial product, and then they are running trial a little bit later. So, how do you view that data, first of all? And then, how you think about the impact for them to be approved in the R/R setting before any of you become, having a first-line label?

Brian Powl
Chief Commercial Officer, Kura Oncology

Who takes the data?

Mollie Leoni
Chief Medical Officer, Kura Oncology

Yeah. So first, I don't think we actually know what the monotherapy data is yet. I know that they published some safety data and their efficacy evaluable data. That's vastly different from an intent to treat patient population. So, they've removed the patients that probably dropped out in the first cycle, so either through to toxicity or rapid progression. That's not the same thing as what any of the other competitors are presenting, what we presented, what's in our label, what will be in J&J's label. So, really what you saw is their best foot forward, but it will come down significantly, if I could bet all of everyone here's money.

Moderator

We'll have to bet the conditions.

Mollie Leoni
Chief Medical Officer, Kura Oncology

I see the response rate probably being more in the 20%-30% range, just like all the other menin inhibitors. I also think that monotherapy, it's nice at producing data, but that's an old story. We've all moved on from there. The menin inhibitor story is now in the combination setting, in earlier lines. We've seen some of their data in the combination earlier line settings, and it certainly does not look superior to ours. Ours actually regularly and consistently looks superior, not only in efficacy, but absolutely from a safety perspective. I think that you're just going to continue us to continue to win, not only in the combinations, but in the frontline due to superior safety and likely superior efficacy as well.

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, I'd say from a commercial perspective, our teams knew that there would be multiple menin inhibitors coming into the market. So, it's not a surprise for us. We anticipated that J&J may be coming forward with data. We'll see what data ends up in their label in terms of how we'd be able to look at the differences. But we've also evaluated whether or not this is a winner-take-all market, and it certainly isn't in our minds. I think that we'll have a winner-take-most or have an opportunity, and I really think that the balance of efficacy, safety, combinability, simplicity of dosing, those are going to help us as physicians look to move to combination in the frontline. Being able to combine, not having cytopenias and others to look for, that's something that we think is going to be important to see.

But our teams will be ready to support that, and I think we have confidence that we'll maintain our leadership coming into number of competitors coming forward.

Moderator

Got it. It is not surprising if the target is attractive and the market is big, you will have multiple competitors, but the early mover will have significant advantage. You will see the president of the sales first, second, third. Just two questions. On the molecular level, do you really see meaningful difference among all the menin inhibitors? Particularly if someone can claim, "My data is much better than the other ones," is that real? How much credibility we can see that? Two is, if we are thinking about, because we start to see the physician talking about the sequencing of the menin inhibitor because menin is pretty useful and then very kind of a driver mutation.

If someone you use the first line and then save some of the other menin inhibitor as a second line, do you think Zifto will be better suited as a first line, second line? Or maybe it is the best drug, you should be using first line, but it can also be used as a second line if you decide to use other drug.

Mollie Leoni
Chief Medical Officer, Kura Oncology

I think the biggest difference between each of these molecules is the PK, and the fact that we are once-a-day dosing, very long half-life, et cetera, plays really well for this particular indication. We also have menin degrader, which, so in addition to inhibiting, we are also degrading the molecule. The others have twice-a-day dosing, much shorter half-lives, and I think that pulsatile hitting of the target is what you see that results in the cytopenias, and potentially in these adaptations of MEN1 resistance that I think the second part of the question was leading up to. I think MEN1 resistance is a big issue in monotherapy.

What we have shown is that it is not an issue for ziftomenib, that we have among the lowest levels of MEN1 resistance mutations, and I believe there is another paper coming at ASH that will also show that we did not write, so it is from an independent source. Whereas, you look at revumenib, it has about a 40% MEN1 resistance mutation developing. What does that tell me as a physician? It tells me that there is no way I would use one that causes a huge percentage of MEN1 mutations upfront, because then you ruin the whole class for these patients moving forward. We have seen physicians that they want to say, "Okay, well, I have got my Ven as a backbone, but I should put a menin inhibitor in there," because they still have menin-dependent disease.

They want that ability throughout the cycle of disease for these patients. I do not see why you would use up your chance earlier on by not using something that does not cause MEN1 mutations at high rates first.

Moderator

Got it. Okay, fantastic. We see the competition is heating up, and then everyone knows the real prize is in the first line. I think Kura, the frontline design is very unique and innovative, and very advantageous. Maybe, Mollie, you designed the trial, then try to give me the quote on that. How you think about, as you have more menin inhibitor coming to the first line, and then how you make sure your enrollment is on track even faster, and then this chemo-intensive versus menin-intensive cohort, and then how we should think about the sequence of the readout going to look like?

Mollie Leoni
Chief Medical Officer, Kura Oncology

Sure. Our frontline trial is our menin, our KOMET-017 trial. What we did was rather than doing two separate trials or doing one as a company-sponsored and one as a consortium-sponsored with HOVON or something along those lines, is to do them both ourselves. We thought it was important enough that we had the control over the data, over the design, et cetera. What we did was put an intensive chemo option and a non-intensive chemo option into one protocol. Any patient with an NPM1 KMT2A disease that walks into a physician's office, newly diagnosed, has a place to go. It makes it so much easier from a feasibility perspective for the sites, because they just have to get one trial up and running, whereas others get two.

Most of these sites are not going to take on more than one pivotal trial in the same sort of indication, because they just do not have the patients to enroll that. Really getting in there first with this one-stop shop for patients was very big, and that is really how we feel very secure that we will do well as more continue to come to the frontline with studies, because we are already there offering a much better option, much easier option for them to enroll in. The enrollment is going fantastic. Thankfully, we did a very large phase I-A, I-B, so we understood what the patient population looked like, what the patients were going to go to as they came into this trial. We were able to absolutely appropriately estimate the enrollment rate, and that is why we are very confident.

When we tell you that we will be able to give initial data on the accelerated approval endpoint for the intensive chemo option in 2028. The accelerated approval endpoint for the VenAza option, the non-intensive chemo, will be shortly thereafter, although we haven't guided specifically. Then I honestly hope that the event-driven endpoints for full approval drag for a while, showing that we're really doing something for these patients. But 2028 is the start of our official foray into the frontline.

Moderator

Got it. Okay, great. Then for the, I think for the I have one. So for the geography, you mentioned one point very important. Most of the sites, they will only do one pivotal trial for one class, right? Where your sites are, which means it will be more exclusive to other menin inhibitor. Then if-

Mollie Leoni
Chief Medical Officer, Kura Oncology

Yeah. About half of our sites are in the U.S. We actually did box out competitors a great deal from the U.S. They've had to go to China and some other regions that the FDA doesn't always review as favorably. Then we have a whole lot of sites in both the E.U. and in Asia Pacific. So we're pretty well-rounded, but with good representation from all the major institutions.

Moderator

Any meaningful difference for the patient from U.S. versus E.U., Asia Pacific, will potentially impact the outcome, final drug arm or maybe the comparator arm as well?

Mollie Leoni
Chief Medical Officer, Kura Oncology

Yeah. Unlike what we saw maybe with the post-transplant maintenance, where differences in therapies leading up to the transplant influenced the outcome, I do not think we are going to have that same issue here. The regional differences should not really manifest, especially in this controlled trial. I think that we are set up for success.

Moderator

Got it. Okay. Maybe lastly, Jennifer.

Jennifer Fulk
CFO, Kura Oncology

Yeah.

Moderator

You have a very good partnership with Kyowa Kirin and then share a lot of the cost and then also commercial. You also have the significant milestones coming. How is Kura financed and funded, considering this menin franchise? We did not talk about FTI for sure. I know you definitely focus a lot more, and we will have more data next year. How is the financial situation and then supporting all the pipeline and commercial?

Jennifer Fulk
CFO, Kura Oncology

Yeah. We had $490 million in cash at the end of the third quarter. We also talked about $180 million coming in milestones that we would start to see next year supporting the phase III trials in ziftomenib. We also announced some pretty exciting information for darlifarnib, our FTI platform. As we thought about funding, we had the opportunity to introduce some more flexibility and capacity to be able to fund not only the ziftomenib, our operating plan for that product, but also to advance darlifarnib. Specifically, we announced that we had reached FDA alignment for a 40-patient registrational study in HRAS mutant salivary gland cancer, and that we plan to start next year, which would be a quicker route to a first full registration for darlifarnib.

We also have additional combination trials going on in solid tumors that we are really excited about for next year. We expect RCC phase I-B data in the second half of next year, and we could have potentially early data in PDAC. As we thought about our capital plan over the next several quarters, it was intended to provide flexibility and capacity as we move through those milestones, and not be dependent on any single milestone to be able to need capital at that time. With our current plan, we can fund all of this and still have plenty of capacity by the time we hit those first top-line results in 2028.

Moderator

Excellent. Thank you so much, Kura team. Thank you, everyone, for-